Methotrexate bias skewing RA trials


Suboptimal doses of methotrexate used in key RA trials may have biased results in favour of new biologic agents, experts claim. Writing in a concise report in the Annals of the Rheumatic Diseases rheumatologist David Felson from Arthritis Research UK and colleagues said numerous studies had demonstrated that pharmaceutical company sponsored trials were often more ...


Already a member? Login to keep reading


OR
© 2017 the limbic